Patents by Inventor Fionnuala Mcaleese-Eser

Fionnuala Mcaleese-Eser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD3 binding domains
    Patent number: 10066015
    Abstract: The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: September 4, 2018
    Assignee: Affirmed GmbH
    Inventors: Eugene Zhukovsky, Melvyn Little, Stefan Knackmuss, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Markus Eser, Fionnuala McAleese-Eser
  • CD3 BINDING DOMAINS
    Publication number: 20160039934
    Abstract: The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.
    Type: Application
    Filed: August 6, 2015
    Publication date: February 11, 2016
    Inventors: Eugene ZHUKOVSKY, Melvyn Little, Stefan Knackmuss, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Markus Eser, Fionnuala Mcaleese-Eser